facebook pixel
chevron_right Top
transparent transparent
Teva migraine drug gets US FDA approval, bolstering turnaround plan
Teva Pharmaceutical Industries Ltd won US regulatory approval to sell a new treatment for migraines, a key part of the company's turnaround strategy. Ajovy's launch could help Teva, the world's largest generic drugmaker, eventually replace declining sales of Copaxone, its aging star product. Investors have tracked the new drug's trajectory as one of the few channels of growth for the debt-ladden pharma giant.
For the best experience use Awesummly app on your Android phone
Awesummly Chrome Extension Awesummly Android App